ArticleAfrican journal of traditional, complementary, and alternative medicines : AJTCAM2013
Nigella sativa concoction induced sustained seroreversion in HIV patient.
Article in African journal of traditional, complementary, and alternative medicines : AJTCAM, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- The Effect of Short Treatment with Nigella Sativa on Symptoms, the Cluster of Differentiation (CD) Profile, and Inflammatory Markers in Mild COVID-19 Patients: A Randomized, Double-Blind Controlled Trial.International journal of environmental research and public health · 2022Trial
- Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial.Complementary therapies in medicine · 2021Trial
- Molecular docking insights of Nigella sativa compounds as potential antiviral inhibitory agents against the replication-machinery proteins VPg and RdRP in rabbit hemorrhagic disease virus (RHDV).Virology journal · 2025Article
- Diversity of Ethiopian Black Cumin (Biochemistry research international · 2025Article
- Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection.Frontiers in pharmacology · 2024Article
- Potential Pharmacological Applications ofPlants (Basel, Switzerland) · 2023Review
- Cellular, Molecular, Pharmacological, and Nano-Formulation Aspects of Thymoquinone-A Potent Natural Antiviral Agent.Molecules (Basel, Switzerland) · 2023Review
- Exploring the inhibitory potential ofRSC advances · 2023Article
- A Narrative Review on Various Oil Extraction Methods, Encapsulation Processes, Fatty Acid Profiles, Oxidative Stability, and Medicinal Properties of Black Seed (Foods (Basel, Switzerland) · 2022Review
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ThymoQuinone Formula (TQF) for Treating Outpatient SARS-CoV-2.Pathogens (Basel, Switzerland) · 2022Article
- Identification of SARS-CoV-2 RNA-dependent RNA polymerase inhibitors from the major phytochemicals ofSaudi journal of biological sciences · 2022Article
- Indazole and its Derivatives in Cardiovascular Diseases: Overview, Current Scenario, and Future Perspectives.Current topics in medicinal chemistry · 2022Review
- Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge.Frontiers in pharmacology · 2022Review
- Thymoquinone against infectious diseases: Perspectives in recent pandemics and future therapeutics.Iranian journal of basic medical sciences · 2021Review
- Black Cumin (Nutrients · 2021Review
- Combating COVID-19: The role of drug repurposing and medicinal plants.Journal of infection and public health · 2021Review
- Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID-19 prevention and cure.Phytotherapy research : PTR · 2021Review
- Thymoquinone: A Promising Natural Compound with Potential Benefits for COVID-19 Prevention and Cure.Drug design, development and therapy · 2021Review
- Prophetic Medicine-Nigella Sativa (Black cumin seeds) - Potential herb for COVID-19?Journal of pharmacopuncture · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nigella sativa had been documented to possess many therapeutic functions in medicine but the least expected is sero-reversion in HIV infection which is very rare despite extensive therapy with highly active anti-retroviral therapy (HAART). This case presentation is to highlight the complete recovery and sero-reversion of adult HIV patient after treatment with Nigella sativa concoction for the period of six months. The patient presented to the herbal therapist with history of chronic fever, diarrhoea, weight loss and multiple papular pruritic lesions of 3 months duration. Examination revealed moderate weight loss, and the laboratory tests of ELISA (Genscreen) and western blot (new blot 1 & 2) confirmed sero-positivity to HIV infection with pre-treatment viral (HIV-RNA) load and CD4 count of 27,000 copies/ml and CD4 count of 250 cells/ mm(3) respectively. The patient was commenced on Nigella sativa concoction 10 mls twice daily for 6 months.. He was contacted daily to monitor side-effects and drug efficacy. Fever, diarrhoea and multiple pruritic lesions disappeared on 5th, 7th and 20th day respectively on Nigella sativa therapy. The CD4 count decreased to 160 cells/ mm3 despite significant reduction in viral load (≤1000 copies/ml) on 30th day on N. sativa. Repeated EIA and Western blot tests on 187th day on Nigella sativa therapy was sero-negative. The post therapy CD4 count was 650 cells/ mm(3) with undetectable viral (HIV-RNA) load. Several repeats of the HIV tests remained sero-negative, aviraemia and normal CD4 count since 24 months without herbal therapy. This case report reflects the fact that there are possible therapeutic agents in Nigella sativa that may effectively control HIV infection.
Indexed as
Identifiers
24311845PMC3847425W1982181755What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.